Building Reliable Agentic AI Systems

Bayer rolled in with a big promise: its in-house AI helper, PRINCE, could turn the messy mountain of drug research data into something scientists can actually talk to in plain English. The company says it built a system that can pull answers from scattered reports, studies, and databases instead of forcing researchers to play detective with clunky old keyword searches. On paper, it’s a very shiny story about making early drug research faster, easier, and less painful.

But the real action was in the peanut gallery, where readers immediately split into two camps: thoughtful skeptics and full-time hype police. One of the strongest reactions came from commenters arguing that the article’s most important idea wasn’t the flashy AI at all, but the boring-sounding discipline of deciding what information the system shouldn’t see. Another crowd was less impressed, basically saying the whole parade of “researcher,” “writer,” and “reflection” bots sounds like a nice-looking flowchart with not enough proof behind it. Translation: cool demo, where are the receipts?

Then came the spice. One commenter took a flamethrower to an author bio, asking if “production-ready AI course” is just another way of saying scam alert. Another smelled moderation drama and demanded to know why a critical comment looked “dead,” turning a technical case study into a mini conspiracy thread. Even the shortest comment — “You cannot” — landed like accidental performance art, the perfect deadpan reaction to yet another grand AI claim on the internet.